AR055011A1 - Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco - Google Patents

Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco

Info

Publication number
AR055011A1
AR055011A1 ARP050105313A ARP050105313A AR055011A1 AR 055011 A1 AR055011 A1 AR 055011A1 AR P050105313 A ARP050105313 A AR P050105313A AR P050105313 A ARP050105313 A AR P050105313A AR 055011 A1 AR055011 A1 AR 055011A1
Authority
AR
Argentina
Prior art keywords
preparation
pharmaco
tetrahydroquinoline compound
composite
preparation process
Prior art date
Application number
ARP050105313A
Other languages
English (en)
Spanish (es)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR055011A1 publication Critical patent/AR055011A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ARP050105313A 2004-12-18 2005-12-16 Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco AR055011A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung

Publications (1)

Publication Number Publication Date
AR055011A1 true AR055011A1 (es) 2007-08-01

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105313A AR055011A1 (es) 2004-12-18 2005-12-16 Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco

Country Status (27)

Country Link
US (2) US8124775B2 (https=)
EP (1) EP1828137B1 (https=)
JP (1) JP5132317B2 (https=)
KR (1) KR20070090248A (https=)
AR (1) AR055011A1 (https=)
AT (1) ATE555097T1 (https=)
AU (1) AU2005315770B2 (https=)
BR (1) BRPI0519602A2 (https=)
CA (1) CA2591397A1 (https=)
CU (1) CU23452B7 (https=)
CY (1) CY1112887T1 (https=)
DK (1) DK1828137T3 (https=)
DO (1) DOP2005000259A (https=)
ES (1) ES2384980T3 (https=)
GT (1) GT200500377A (https=)
IL (1) IL184008A (https=)
MA (1) MA29100B1 (https=)
MX (1) MX2007007188A (https=)
NO (1) NO20073146L (https=)
PE (1) PE20060767A1 (https=)
PL (1) PL1828137T3 (https=)
PT (1) PT1828137E (https=)
RU (1) RU2393151C2 (https=)
SI (1) SI1828137T1 (https=)
TW (1) TW200635900A (https=)
UY (1) UY29276A1 (https=)
WO (1) WO2006063828A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
DK2268644T3 (da) * 2008-03-05 2011-10-10 Boehringer Ingelheim Int Tricycliske pyridinderivater, medikamenter indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
EA201201160A1 (ru) 2010-02-19 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения
AU2011274903B2 (en) * 2010-07-09 2016-09-08 Daiichi Sankyo Company, Limited Substituted pyridine compound
WO2012110599A1 (en) 2011-02-17 2012-08-23 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
JP5947382B2 (ja) 2011-08-17 2016-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フロ[3,4−c]キノリン誘導体、このような化合物を含む薬物、それらの使用及びそれらの調製方法
ES2599757T3 (es) 2012-01-06 2017-02-03 Daiichi Sankyo Company, Limited Sales de aducto de ácido de un compuesto de piridina sustituido como inhibidores de la proteína de transferencia de ésteres de colesterilo (PTEC)
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
WO2025185022A1 (zh) * 2024-03-05 2025-09-12 维康平生(北京)生物科技有限公司 一种脂肪体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128681A1 (de) * 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) * 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19704244A1 (de) * 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) * 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) * 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors

Also Published As

Publication number Publication date
CU23452B7 (es) 2009-12-01
KR20070090248A (ko) 2007-09-05
CY1112887T1 (el) 2016-04-13
RU2393151C2 (ru) 2010-06-27
AU2005315770B2 (en) 2011-12-08
BRPI0519602A2 (pt) 2009-02-25
PT1828137E (pt) 2012-07-04
JP2008524145A (ja) 2008-07-10
DK1828137T3 (da) 2012-07-23
CA2591397A1 (en) 2006-06-22
AU2005315770A1 (en) 2006-06-22
ATE555097T1 (de) 2012-05-15
TW200635900A (en) 2006-10-16
US20080255068A1 (en) 2008-10-16
PL1828137T3 (pl) 2012-09-28
RU2007127127A (ru) 2009-01-27
WO2006063828A1 (de) 2006-06-22
US20120142728A1 (en) 2012-06-07
IL184008A0 (en) 2007-10-31
MA29100B1 (fr) 2007-12-03
EP1828137B1 (de) 2012-04-25
GT200500377A (es) 2006-11-09
PE20060767A1 (es) 2006-09-10
EP1828137A1 (de) 2007-09-05
ES2384980T3 (es) 2012-07-16
IL184008A (en) 2012-03-29
SI1828137T1 (sl) 2012-08-31
MX2007007188A (es) 2007-08-14
JP5132317B2 (ja) 2013-01-30
UY29276A1 (es) 2006-07-31
US8124775B2 (en) 2012-02-28
DOP2005000259A (es) 2006-11-15
NO20073146L (no) 2007-09-18

Similar Documents

Publication Publication Date Title
CY1112369T1 (el) 2-μεθυλο-2-[4-(3-μεθυλο-2-οξο-8-κινολιν-3-υλο-2,3-διϋδρο-ιμιδαζο[4,5-c]κινολινυλο)-φαινυλο]προπιονιτριλιο ως αναστολεας λιπιδικης κινασης
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
BRPI0413490A (pt) novos compostos
PA8680701A1 (es) Derivados de oxindol
BR0010555A (pt) Inibidores de neuraminidases
NO20016001D0 (no) Substituert fenylpropansyrederivater som agonister for human peroksisom proliferantaktivert reseptor (PPAR)<alfa>
ES467828A1 (es) Un procedimiento para preparar nuevos compuestos de cefem y cefam
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
TW200833682A (en) Pharmaceutical compounds
AR039789A1 (es) Pirazolopiridinas sustituidas con carbamato
UY30426A1 (es) Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones.
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
DOP2006000235A (es) Derivados de acidos dicarboxilicos y su uso
AR055011A1 (es) Compuesto de tetrahidroquinolina, proceso de preparacion del compuesto y su uso para la preparacion de un farmaco
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
AR051754A1 (es) Metodos para preparar compuestos de indazol
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
ITMI20050801A1 (it) Procedimento per la preparazione di telmisartan
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
ATE281432T1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
CR10038A (es) Analogo de la diazonamida a

Legal Events

Date Code Title Description
FA Abandonment or withdrawal